J&J, Sputnik & Sinopharm vaccines ineffective against Omicron: Study - Kalkine Media

December 18, 2021 03:32 AM AEDT | By Versha Jain
Follow us on Google News:


  • The latest research study by the University of Washington and Humabs Biomed SA showed existing vaccines are not very effective against Omicron.
  • The research study analyzed six vaccines.
  • The study is not yet peer-reviewed.

The latest research study by the University of Washington and Humabs Biomed SA, a unit of Vir Biotechnology, showed that the COVID-19 vaccines made by China’s Sinopharm, Johnson and Johnson of the US, and Sputnik developed by Russia are not considerably effective against the Omicron variant of coronavirus. It was found that these vaccines generate very little or no antibodies against the variant.  

The research study analyzed six vaccines’ efficacy against the highly infectious virus mutant, Omicron.  The study showed that with the Sinopharm vaccine, only three out of 13 people generated antibodies against the virus. At the same time, it was only one out of 12 samples with the Johnson and Johnson vaccine, and no one generated any antibodies out of 11 people fully vaccinated with Sputnik.     

Also Read: Top 5 US bank stocks to watch amid Fed’s tapering of asset purchases

The other three vaccines studied were Pfizer-BioNTech, Moderna, and vector vaccine developed by the University of Oxford and AstraZeneca Plc. Pfizer-BioNTech and Moderna vaccines were found to have generated fewer antibodies in people who have taken two doses. At the same time, the AstraZeneca vaccine was also found to have less protection against the virus.  

The research studies earlier also showed that the Sinovac Biotech Ltd’s vaccine with two doses is not as sufficient against Omicron. So, there may be a need for a booster dose to protect against it. 

Also Read: Best US ETFs that returned over 55% in 2021   

 (JNJ, Sinopharm and Sputnik are less effective against Omicron; study reveals)

Also Read: These 5 US stocks returned between 500% and 5,000% in 2021

Though the study is not yet peer-reviewed, its revelations today has created jitters among investors amid prospective uncertainties in the economies globally.

Omicron is the most easily infectious variant of the coronavirus and has spread in over 77 countries almost within a month from when the first case was reported in South Africa. Governments are still not sure about how deadly it is.

Also Read: Top 5 US retail stocks to watch amid holiday shopping season

On the one hand, researchers are working and finding the efficacy of vaccines through studying the immune responses of people after undertaking the vaccine. On the other, research is still ongoing for studying cell-mediated immunity, better known as T-cells response against Omicron.

Scientists and people in the healthcare industry are striving to find a solution to the health crisis. Ideas of developing a third dose or using a combination of different existing vaccines are being considered to achieve sure shot protection against Omicron.  

Also Read: DiCaprio-backed Rubicon to go public with Founder in $2B SPAC deal

 J&J, Sputnik & Sinopharm vaccines ineffective against Omicron: Study

Bottom line

After the study was published today, stocks of vaccine makers fell. Pfizer, Inc. (PFE) was down around 2%, Moderna, Inc. (MRNA) stock decreased 2.27%, AstraZeneca (AZN) declined 0.7%, and Johnson & Johnson (JNJ) plunged more than 2%, intraday.


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Top ASX Listed Companies

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK